InsidersTradesSigma
Follow the Globus Medical INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Globus Medical INC has published 73 public disclosures. Market capitalisation: €11.6bn. The latest transaction was filed on 19 August 2026 (Levée d'options). Among the most active insiders: Davidar David D. Every trade is openly available.
73
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€13m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Globus Medical INC Buy (bullish), based on 13 analysts. Average price target: US$103.23.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,057 of 28,717 companies
68.3
score / 100
Value55
Quality81
FCF yld5.0%
Earn yld4.6%
EV/EBITDA14.5x
ROE12%
Gross mgn67%
Net mgn18%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations73 total
25,000 shares@ US$53.27Class A Common StockSEC:0001193125-26-357121:0
25,000 shares@ US$87.0386Class A Common StockSEC:0001193125-26-357121:1
25,000 shares@ US$87.040.019% mcap66.3% of flowCommonSEC144:0001974078-26-000312
2,500 shares0Class A Common StockSEC:0001193125-26-321442:0
25,000 shares@ US$26.270.0052% mcap5.9% of flowClass A Common StockSEC:0001193125-26-263997:0
25,000 shares@ US$80.76290.016% mcap18.3% of flowClass A Common StockSEC:0001193125-26-263997:1
25,000 shares@ US$81.000.018% mcap14.8% of flowCommonSEC144:0001974078-26-000224
20,000 shares@ US$43.5838.2% of flowClass A Common StockSEC:0001193125-26-083348:0
10,000 shares@ US$45.6419.8% of flowClass A Common StockSEC:0001193125-26-055137:0
3,594 shares@ US$51.8748.9% of flowClass A Common StockSEC:0001193125-26-010699:0
2,000 shares@ US$101.1016.6% of flowClass A Common StockSEC:0001193125-26-010697:0
6,100 shares0Class A Common StockSEC:0001193125-26-002966:0
4,000 shares@ US$88.8534.7% of flowClass A Common StockSEC:0001193125-25-320898:0
34,375 shares@ US$25.5255.8% of flowClass A Common StockSEC:0001193125-25-314329:0
3,646 shares@ US$53.14100.0% of flowClass A Common StockSEC:0001193125-25-307215:0
7,500 shares@ US$25.9620.8% of flowClass A Common StockSEC:0001193125-25-302649:0
25,000 shares@ US$25.525.5% of flowClass A Common StockSEC:0001193125-25-280500:0
25,000 shares@ US$44.14100.0% of flowClass A Common StockSEC:0001193125-25-280472:0
8,000 shares@ US$81.0027.5% of flowClass A Common StockSEC:0001193125-25-274288:0
10,000 shares@ US$58.4633.6% of flowClass A Common StockSEC:0001193125-25-205135:0
7,500 shares@ US$78.6857.9% of flowClass A Common StockSEC:0000950170-25-032220:0
5,833 shares@ US$49.6510.1% of flowClass A Common StockSEC:0000950170-25-005353:0
2,500 shares@ US$24.218.9% of flowClass A Common StockSEC:0000950170-24-133260:0
13,278 shares@ US$65.0546.9% of flowClass A Common StockSEC:0000950170-24-130597:0
50,000 shares@ US$43.7741.9% of flowClass A Common StockSEC:0000950170-24-130588:0
25 of 73 declarations
About Globus Medical INC
Globus Medical Inc. (NYSE: GMED) is a United States-listed medical technology company traded on the NYSE and headquartered in Audubon, Pennsylvania, United States. Founded in 2003, the company has built its business around musculoskeletal solutions, with an especially strong franchise in spine, and a broader presence in orthopedic trauma, joint reconstruction, regenerative biomaterials, and enabling technologies. Its model combines product design, manufacturing, commercialization, and clinical support, giving it a vertically integrated platform that is intended to serve surgeons and hospitals with procedure-based solutions rather than isolated products. ([investors.globusmedical.com](https://investors.globusmedical.com/?utm_source=openai)) From an equity analyst perspective, GMED is positioned in a structurally attractive market. Demand is supported by aging populations, the prevalence of spinal disorders, and the ongoing shift toward more efficient, less invasive procedures. Globus differentiates itself through a sustained innovation culture, a broad procedural portfolio, and a high-touch commercial model that aims to maintain close relationships with surgeons and care teams. The company describes itself as a single operating platform, which helps align research, development, manufacturing, education, and sales around unmet clinical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000156276225000026/gmed-20241231x10k.htm?utm_source=openai)) The company’s roots are in spine, where it initially established its brand and technical credibility, before expanding into adjacent musculoskeletal categories. In recent years, its strategic profile has become more ambitious through major transactions, most notably the NuVasive acquisition and the completion of the Nevro acquisition in 2025. Management has emphasized that integration remains a core operational priority, alongside a robust new-product pipeline and continued investment in commercial execution. ([investors.globusmedical.com](https://investors.globusmedical.com/news-events/press-releases?utm_source=openai)) Geographically, Globus derives the majority of its business from the United States, while also maintaining international activity through distributors and non-U.S. commercial channels. Recent disclosures point to solid momentum: the company reported 2025 full-year sales of $2.9389 billion, up 16.7%, with fourth-quarter growth driven by the core spine franchise and enabling technologies. In early 2026, management reiterated its focus on above-market growth, product innovation, and disciplined execution as it works through the integration of its acquisitions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-ye2025ex991.htm?utm_source=openai)) Overall, Globus Medical can be viewed as a growth-oriented healthcare technology company with a meaningful U.S. spine franchise, expanding procedural breadth, and a strategy centered on innovation, scale, and acquisition integration. ([investors.globusmedical.com](https://www.investors.globusmedical.com/news-events/press-releases?utm_source=openai))
